The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Updates from CAPTIVATE: ibrutinib and venetoclax for CLL
Tanya Siddiqi, MD, of the City of Hope National Medical Center, Duarte, CA, discusses the efficacy and safety results of the use of ibrutinib and venetoclax for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
